Updated:
Pierre Fabre
The Pierre Fabre group was founded in 1962 by Pierre Fabre, a pharmacist and researcher who developed the first molecule for treating prostate disorders.
Pierre Fabre
The Pierre Fabre group was founded in 1962 by Pierre Fabre, a pharmacist and researcher who developed the first molecule for treating prostate disorders. The company grew into a global pharmaceutical and dermo-cosmetics enterprise, best known for brands such as Klorane, Avene, Ducray, and René Furterer, and for its oncology and dermatology R&D. The family office responsible for the group's founding wealth is based in Castres, France, and situates its capital within the broader corporate structure. The office's investment activity is not publicly detailed, but the group's strategic allocations suggest a focus on healthcare-adjacent sectors and real estate. The group itself operates across more than 100 countries, with R&D centers in France, Spain, and the United States, and has a history of partnerships with academic institutions and biotech firms. The family office likely participates in co-investments alongside the group's corporate development arm, though direct investment vehicles are not separately disclosed. Team and governance details for the family office are not public. The Pierre Fabre group is privately held, with ownership concentrated in the founding family and, since 2020, a minority stake held by the Pierre Fabre Foundation, a corporate foundation established to preserve the company's independence and social mission. In July 2023, the group announced the expansion of its dermatology pipeline through a licensing agreement with a Chinese biotech firm (per the company, July 2023). The structural differentiator of the Pierre Fabre wealth is its integration with the founding family's operating company and foundation. Unlike many family offices that operate as independent investment vehicles, the Pierre Fabre family office appears to function as part of the group's broader governance framework, with strategic capital aligned to the group's long-term pharmaceutical and dermo-cosmetics core. This structure allows the family to maintain control over the business while separating philanthropic activities through the Pierre Fabre Foundation.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Castres
Corporate office
Castres, Occitanie, France
Sector focus
Frequently asked questions
Who manages investment decisions at the Pierre Fabre family office?
The Pierre Fabre family office is not a publicly disclosed entity; its leadership and investment committee structure are not on the public record. The Pierre Fabre group itself is governed by a board of directors that includes family members and external advisors. Investment decisions likely sit with the group's finance and corporate development team, operating under the oversight of the founding family.
How does the Pierre Fabre family office source proprietary deal flow?
As the investment arm of a major pharmaceutical and dermo-cosmetics group, the Pierre Fabre office sources opportunities through the group's extensive R&D network, academic partnerships, and licensing agreements. The group's presence in over 100 countries provides direct access to healthcare and life sciences startups, particularly in dermatology and oncology.
Is the Pierre Fabre family office structured as a single family office or does it operate more like a corporate venture arm?
Public information suggests the Pierre Fabre family office is structured as a single family office integrated within the wider Pierre Fabre group, rather than as a standalone venture firm. The group has a dedicated corporate development function that handles M&A, licensing, and strategic investments, but no separate family office vehicle has been publicly identified.
What investment stages does the Pierre Fabre family office typically target?
Specific investment stages are not publicly documented. The group's corporate development activity suggests a focus on early-stage to mid-stage biotech and pharmaceutical partnerships, licensing deals, and acquisition of dermatology and cosmetic brands. The family office likely participates in direct investments and co-investments with the group's operating companies.
Does the Pierre Fabre family office maintain philanthropic structures?
Yes. The Pierre Fabre Foundation is a corporate foundation established in 2010 with the mission to preserve the group's independence and social commitment. The foundation holds a minority stake in the Pierre Fabre group and funds projects in dermatology, public health, and environmental sustainability. It is separate from the family office's investment operations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: